The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

CNBC's Kristina Partsinevelos joins 'Closing Bell' to discuss the stocks she's watching.

Moderna Chairman Noubar Afeyan says the trial results remind him of when his company developed its Covid-19 vaccine.

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

Moderna shares soared more than 172% after strong results for its vaccine for melanoma skin cancer. Elsewhere, the Evergrande ...

Moderna and Merck announced that a personalized mRNA melanoma vaccine met key goals in a Phase 3 trial. It could become ...

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known ...

Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of ...

Moderna (MRNA) is back in focus after reporting that its personalized mRNA cancer therapy intismeran achieved primary and key ...

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.

If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.